Evidence map›Paper›PMID 30066860›Full record

ArticleInternational journal of oncology2018

Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.

Charles-Henry Gattolliat, Sophie Couvé, Guillaume Meurice, Cédric Oréar, Nathalie Droin, Mathieu Chiquet, Sophie Ferlicot, Virginie Verkarre, Viorel Vasiliu, Vincent Molinié and 8 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Non-Coding RNAs in Hereditary Kidney Disorders.International journal of molecular sciences · 2021
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Charles-Henry GattolliatOncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France.
Sophie CouvéOncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France.
Guillaume MeuriceBioinformatic Platform, 94800 Villejuif, France.
Cédric OréarGenomic Platform, Gustave Roussy, 94800 Villejuif, France.
Nathalie DroinGenomic Platform, Gustave Roussy, 94800 Villejuif, France.
Mathieu ChiquetOncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France.
Sophie FerlicotINSERM, UMR 1186, Gustave Roussy, Paris-Sud University, Paris-Saclay University, 94800 Villejuif, France.
Virginie VerkarrePREDIR INCa, Department of Urology, AP-HP, Bicêtre Hospital, 94270 Le Kremlin-Bicêtre, France.
Viorel VasiliuDepartment of Pathological Anatomy, Necker Hospital, 75015 Paris, France.
Vincent MoliniéDepartment of Pathological Anatomy and Cytology, Saint Joseph Hospital, 75014 Paris, France.
Arnaud MéjeanPREDIR INCa, Department of Urology, AP-HP, Bicêtre Hospital, 94270 Le Kremlin-Bicêtre, France.
Philippe DessenBioinformatic Platform, 94800 Villejuif, France.
Sophie GiraudPREDIR INCa, Department of Urology, AP-HP, Bicêtre Hospital, 94270 Le Kremlin-Bicêtre, France.
Brigitte Bressac-De-PailleretsINSERM, UMR 1186, Gustave Roussy, Paris-Sud University, Paris-Saclay University, 94800 Villejuif, France.
Betty GardieOncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France.
Bin Tean TehNational Cancer Centre, Duke Graduate Medical School, Cancer Science Institute of Singapore, Institute of Molecular and Cellular Biology, Singapore 138673, Singapore.
Stéphane RichardOncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France.
Sophie GadOncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France.
École Pratique des Hautes Études · FRAssistance Publique – Hôpitaux de Paris · FRInstitut Gustave Roussy · FRLaboratoire d'études sur les monothéismes · FRUniversité Paris-Sud · FRHôpital Necker-Enfants Malades · FRHôpital Saint Joseph · FRNational Cancer Centre Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Von Hippel-Lindau (VHL) disease is a rare autosomal dominant syndrome that is the main cause of inherited clear-cell renal cell carcinoma (ccRCC), which generally occurs in the form of multiple recurrent synchronized tumors. Affected patients are carriers of a germline mutation in the VHL tumor suppressor gene. Somatic mutations of this gene are also found in sporadic ccRCC and numerous pan-genomic studies have reported a dysregulation of microRNA (miRNA) expression in these sporadic tumors. In order to investigate the molecular mechanisms underlying the pathogenesis of VHL-associated ccRCC, particularly in the context of multiple tumors, the present study characterized the mRNA and miRNA transcriptome through an integrative analysis compared with sporadic renal tumors. In the present study, two series of ccRCC samples were used. The first set consisted of several samples from different tumors occurring in the same patient, for two independent patients affected with VHL disease. The second set consisted of 12 VHL-associated tumors and 22 sporadic ccRCC tumors compared with a pool of normal renal tissue. For each sample series, an expression analysis of miRNAs and mRNAs was conducted using microarrays. The results indicated that multiple tumors within the kidney of a patient with VHL disease featured a similar pattern of miRNA and gene expression. In addition, the expression levels of miRNA were able to distinguish VHL-associated tumors from sporadic ccRCC, and it was identified that 103 miRNAs and 2,474 genes were differentially expressed in the ccRCC series compared with in normal renal tissue. The majority of dysregulated genes were implicated in 'immunity' and 'metabolism' pathways. Taken together, these results allow a better understanding of the occurrence of ccRCC in patients with VHL disease, by providing insights into dysregulated miRNA and mRNA. In the set of patients with VHL disease, there were few differences in miRNA and mRNA expression, thus indicating a similar molecular evolution of these synchronous tumors and suggesting that the same molecular mechanisms underlie the pathogenesis of these hereditary tumors.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overCarcinoma, Renal CellCase-Control StudiesCell Line, TumorFemaleGene Expression ProfilingHumansKidneyKidney NeoplasmsMaleMicroRNAsMiddle AgedNeoplasm Recurrence, LocalMicroRNAsRNA, MessengerVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID30066860
PMCPMC6086628
OpenAlexW2884735144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.